GFAP and Alzheimer disease: Sensitivity analyses, which excluded the 12 cases with AD positive biomarkers, yielded consistent results with our primary findings with one exception observed in the correlation analysis between disease duration postblood sampling and GFAP levels in the deceased bvFTD subgroup.